首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL5 |
| Uniprot No | P13501 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-91aa |
| 氨基酸序列 | SPYSSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS |
| 预测分子量 | 14.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Expression and Purification of Recombinant CCL5 in Escherichia coli for Functional Studies"**
- *Author: Zhang Y, et al.*
- **摘要**: 报道了在大肠杆菌中高效表达带有His标签的重组CCL5蛋白，通过镍柱亲和层析纯化，并验证其对T淋巴细胞的趋化活性，为体外免疫研究提供工具。
2. **"Glycosylation Modulates the Chemotactic Activity of Recombinant CCL5 in Mammalian Cells"**
- *Author: Smith JA, et al.*
- **摘要**: 在HEK293细胞中表达糖基化重组CCL5.发现糖基化修饰影响其与受体CCR5的结合能力及体内外趋化功能，提示翻译后修饰的重要性。
3. **"Recombinant CCL5 Antagonizes HIV-1 Infection via CCR5 Downregulation"**
- *Author: Jones LM, et al.*
- **摘要**: 利用重组CCL5蛋白阻断HIV-1与宿主细胞CCR5受体的结合，体外实验显示其显著抑制病毒进入，为抗病毒治疗提供潜在策略。
4. **"Structural Analysis of Recombinant CCL5 by NMR Reveals Key Residues for Receptor Interaction"**
- *Author: Lee S, et al.*
- **摘要**: 通过核磁共振解析重组CCL5的溶液结构，鉴定出与CCR5结合的关键氨基酸残基，为靶向药物设计提供结构基础。
---
*注：以上文献信息为模拟示例，实际引用需查询具体数据库(如PubMed)并核对原文。*
**Background of CCL5 Recombinant Protein**
CCL5 (C-C motif chemokine ligand 5), also known as RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted), is a small cytokine belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting leukocytes, including T cells, monocytes, eosinophils, and dendritic cells, to sites of inflammation or infection. CCL5 binds to G-protein-coupled receptors CCR1. CCR3. and CCR5. triggering intracellular signaling pathways that mediate cell migration, activation, and survival. Its expression is induced in activated T cells, endothelial cells, and fibroblasts, often in response to pro-inflammatory cytokines like TNF-α or viral infections.
Recombinant CCL5 protein is produced using genetic engineering techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and bioactivity. This engineered form retains the native protein’s functional properties, enabling researchers to study its role in vitro and in vivo. CCL5 is implicated in various pathological processes, including chronic inflammatory diseases (e.g., arthritis, atherosclerosis), autoimmune disorders, and viral infections (notably HIV, where it competes with viral entry by blocking CCR5). Conversely, it also exhibits dual roles in cancer, either promoting tumor progression by supporting angiogenesis and immune evasion or suppressing metastasis through immune activation.
Therapeutic targeting of CCL5 or its receptors is under investigation for conditions like HIV, inflammatory disorders, and cancer. Recombinant CCL5 serves as a vital tool for elucidating immune cell interactions, screening drug candidates, and developing biomarker-based diagnostics. However, its pleiotropic effects necessitate careful evaluation in clinical applications to balance beneficial and adverse outcomes.
×
